Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8346446 | 0.92 | GAA (0.54) | NAAAFAAHCASP2EPHX1GAA | |
| SCHEMBL9130017 | 0.86 | PAOX (0.52) | NAAAFAAHCASP2GAAMGAM | |
| SCHEMBL13129294 | 0.86 | CASP2 (0.65) | NAAAFAAHCASP2EPHX1L3MBTL1 | |
| SCHEMBL13825075 | 0.85 | EPHX1 (0.62) | NAAAFAAHCASP2EPHX1L3MBTL1 | |
| SCHEMBL23280900 | 0.84 | L3MBTL1 (0.67) | NAAAFAAHCASP2L3MBTL1GAA | |
| SCHEMBL8630173 | 0.84 | L3MBTL1 (0.67) | NAAAFAAHCASP2L3MBTL1GAA | |
| SCHEMBL10629967 | 0.82 | EPHX1 (0.59) | NAAAFAAHCASP2EPHX1L3MBTL1 | |
| SCHEMBL5413855 | 0.82 | EPHX1 (0.50) | NAAAFAAHCASP2EPHX1GAA | |
| SCHEMBL14370358 | 0.82 | CASP2 (0.75) | NAAAFAAHCASP2EPHX1MEN1 | |
| SCHEMBL14890990 | 0.82 | CASP2 (0.75) | NAAAFAAHCASP2EPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049020-B2 | Substituted N -acyl homoserine lactones | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2011-11-01 | — | — | US | disclosed |
| US-20100286261-A1 | SUBSTITUTED N-ACYL HOMOSERINE LACTONES | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2044046-B1 | SUBSTITUTED N-ACYL HOMOSERINE LACTONES | SECR DEFENCE (GB) | 2009-10-21 | — | — | EP | disclosed |
| EP-2044046-A2 | SUBSTITUTED N-ACYL HOMOSERINE LACTONES | The Secretary of State for Defence (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007135466-A2 | SUBSTITUTED N-ACYL HOMOSERINE LACTONES | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286261-A1 | SUBSTITUTED N-ACYL HOMOSERINE LACTONES | COASY, AHCYL1, LSS | NAAA 178/4885FAAH 104/4885CASP2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.